CClinicalTrials.gg
CompletedNCT01959035Updated Mar 17, 2017Results posted

Aripiprazole Once-monthly in Patients With Schizophrenia

A Phase 3 interventional study of Aripiprazole once-monthly in Schizophrenia, sponsored by H. Lundbeck A/S. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-03-17.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
88
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

To obtain information on the safety, tolerability and effectiveness of aripiprazole once-monthly in a manner consistent with its intended use in everyday clinical practice in patients with schizophrenia who completed Study 14724A / NCT01795547.

02

Conditions studied

  • Schizophrenia

Browse trials for

03

In context

Schizophrenia

3,471 studies on the registry are indexed under Schizophrenia; 471 are open to participants now.

This study's enrollment of 88 is above the median of 70 across 2,871 interventional studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

H. Lundbeck A/S is the lead sponsor of 218 studies on the registry; 10 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Patients will be recruited among those who complete treatment with aripiprazole in Study 14724A / NCT01795547.

Inclusion criteria

Inclusion Criteria:

  • The patient is judged to potentially benefit from 24-week treatment with aripiprazole once-monthly according to the clinical opinion of the investigator.
  • The patient agrees to protocol-defined use of effective contraception.

Exclusion criteria

Exclusion Criteria:

  • The patient has been diagnosed with a primary psychiatric disorder other than schizophrenia during Study 14724A / NCT01795547.
  • The patient has a clinically significant unstable illness diagnosed during Study 14724A / NCT01795547.
  • The patient is at significant risk of harming himself/herself or others according to the investigator's judgement or according to Columbia-Suicide Severity Rating Scale (C-SSRS).
  • The patient has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability or efficacy, or interfere with the conduct or interpretation of the study.
  • The patient has one or more clinical laboratory test values outside the reference range, based on the blood or urine samples taken during the conduct of Study 14724A / NCT01795547 that are, in the investigator's opinion, of potential risk to the patient's safety.
  • The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.

Other inclusion and exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Aripiprazole once-monthly

    Drug: Aripiprazole once-monthly

Interventions

  • DrugAripiprazole once-monthly

    400 or 300 mg/month; 6 intramuscular (IM) injections starting at baseline

    Also known as: Abilify Maintena®

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Number of treatment emergent adverse events (TEAEs).

    Time frame: Up to 24 weeks and 4-week safety follow up

Secondary outcomes

  1. Change From Baseline to Week 24 in SWN-S Total Score

    The Subjective Well-Being under Neuroleptic Treatment - Short Version (SWN-S) is a patient-rated scale designed to measure subjective effects of neuroleptic drugs to psychopathology, quality of life, and compliance over the past 7 days. The 20 items (10 positive and 10 negative statements) are grouped in 5 subscales (mental functioning, self-control, physical functioning, emotional regulation and social integration). Each subscale contains 4 items. Each item was rated on a six-point Likert scale, from not at all to very much. A score was calculated for each subscale, and the total score ranged from 20 to 120, where the higher score indicated better well-being.

    Time frame: Baseline and Week 24

  2. Change From Baseline to Week 24 in CGI-S Score

    Clinical Global Impression - Severity of Illness (CGI-S) score provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Baseline and Week 24

  3. Change From Baseline to Week 24 in QLS Total Score

    The Quality of Life Scale (QLS) is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). Definitions were provided for 4 anchor points of the 7 points. Each item had a brief description of the judgement to be made and a set of suggested probes for the clinician. The total score was calculated as the sum of all 21 items giving a range of 0 to 126, where the higher score indicated normal or unimpaired functioning.

    Time frame: Baseline and Week 24

  4. Change From Baseline to Week 24 in the 'Common Objects and Activities' QLS Domain Score

    The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Common Objects and Activities domain score was calculated as the sum of 2 items (numbers 18 and 19) giving a range of 0 to 12, where the higher score indicated less unimpaired functioning

    Time frame: Baseline and Week 24

  5. Change From Baseline to Week 24 in the 'Intrapsychic Foundations' QLS Domain Score

    The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Intrapsychic Foundations domain score was calculated as the sum of 7 items (numbers 13 to 17 and 20 and 21) giving a range of 0 to 42, where the higher score indicated less unimpaired functioning

    Time frame: Baseline and Week 24

  6. Change From Baseline to Week 24 in the 'Interpersonal Relations' QLS Domain Score

    The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Interpersonal Relations domain score was calculated as the sum of 8 items (numbers 1 to 8) giving a range of 0 to 48, where the higher score indicated less unimpaired functioning.

    Time frame: Baseline and Week 24

  7. Change From Baseline to Week 24 in the 'Instrumental Role' QLS Domain Score

    The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Instrumental Role domain score was calculated as the sum of 4 items (numbers 9 to 12) giving a range of 0 to 24, where the higher score indicated less unimpaired functioning.

    Time frame: Baseline and Week 24

  8. Change From Baseline to Week 24 in the TooL Total Score

    Tolerability and Quality of Life (TooL) is a patient-rated scale developed to measure the impact of side-effects on the quality of life in patients treated with antipsychotic medication. The TooL consists of 8 domains: mood (worry-upset), function capabilities, fatigue-weakness, weight gain, stiffness-tremor, physical restlessness, sexual dysfunction, and dizziness-nausea. Each domain was rated on a four-point scale from 1 (no impact) to 4 (maximum impact). Total scores ranged from 8 (no impact) to 32 (maximum impact).

    Time frame: Baseline and Week 24

  9. Change From Baseline to Week 24 in the WoRQ Total Score

    The Readiness for Work Questionnaire (WoRQ) is a clinician-rated scale designed to measure a schizophrenic patient's ability to work. The WoRQ consists of 8 items: the clinician had to rate 7 statements and answer 1 question. The statements were rated on a four-point scale, from 'strongly agree', 'agree', 'disagree' or 'strongly disagree' based on all material available (for example, personal notes, medical records, input from other health professionals, family members or caregivers); and in the final item, the clinician had to indicate if the patient was ready for work or not (by indicating either 'yes' or 'no'). Possible total scores range from 4 to 28. Lower WoRQ total scores indicate better functioning.

    Time frame: Baseline and Week 24

  10. Change From Baseline to Week 24 in ASEX Total Score

    The Arizona Sexual Experience Scale (ASEX) is a five-item, patient-rated scale that evaluates a patient's recent sexual experiences. The ASEX is used to identify individuals with sexual dysfunction. Patients were asked to assess their own experiences over the last week (for example, "How strong is your sex drive?", "Are your orgasms satisfying?") and respond on a six-point scale for each item. Possible total scores range from 5 to 30. Higher ASEX total scores indicate more sexual dysfunction (hypofunction).

    Time frame: Baseline and Week 24

  11. Patients Categorised As Sexually Dysfunctional Measured at Week 24 on the ASEX Scale

    The Arizona Sexual Experience Scale (ASEX) is a five-item, patient-rated scale that evaluates a patient's recent sexual experiences. The ASEX is used to identify individuals with sexual dysfunction. Patients were asked to assess their own experiences over the last week (for example, "How strong is your sex drive?", "Are your orgasms satisfying?") and respond on a six-point scale for each item. Possible total scores range from 5 to 30. Higher ASEX total scores indicate more sexual dysfunction (hypofunction). The presence of sexual dysfunction based on the ASEX scale was defined as an ASEX total score of ≥19, or a score of ≥5 on any item, or a score of ≥4 on any 3 items.

    Time frame: Week 24

  12. Change From Baseline to Week 12 in SWN-S Total Score

    The Subjective Well-Being under Neuroleptic Treatment - Short Version (SWN-S) is a patient-rated scale designed to measure subjective effects of neuroleptic drugs to psychopathology, quality of life, and compliance over the past 7 days. The 20 items (10 positive and 10 negative statements) are grouped in 5 subscales (mental functioning, self-control, physical functioning, emotional regulation and social integration). Each subscale contains 4 items. Each item was rated on a six-point Likert scale, from not at all to very much. A score was calculated for each subscale, and the total score ranged from 20 to 120, where the higher score indicated better well-being.

    Time frame: Baseline and Week 12

  13. Change From Baseline to Week 12 in CGI-S Score

    Clinical Global Impression - Severity of Illness (CGI-S) score provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Baseline and Week 12

  14. Change From Baseline to Week 12 in QLS Total Score

    The Quality of Life Scale (QLS) is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). Definitions were provided for 4 anchor points of the 7 points. Each item had a brief description of the judgement to be made and a set of suggested probes for the clinician. The total score was calculated as the sum of all 21 items giving a range of 0 to 126, where the higher score indicated normal or unimpaired functioning.

    Time frame: Baseline and Week 12

  15. Change From Baseline to Week 12 in the 'Common Objects and Activities' QLS Domain Score

    The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Common Objects and Activities domain score was calculated as the sum of 2 items (numbers 18 and 19) giving a range of 0 to 12, where the higher score indicated less unimpaired functioning

    Time frame: Baseline and Week 12

  16. Change From Baseline to Week 12 in the 'Intrapsychic Foundations' QLS Domain Score

    The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Intrapsychic Foundations domain score was calculated as the sum of 7 items (numbers 13 to 17 and 20 and 21) giving a range of 0 to 42, where the higher score indicated less unimpaired functioning

    Time frame: Baseline and Week 12

  17. Change From Baseline to Week 12 in the 'Interpersonal Relations' QLS Domain Score

    The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Interpersonal Relations domain score was calculated as the sum of 8 items (numbers 1 to 8) giving a range of 0 to 48, where the higher score indicated less unimpaired functioning

    Time frame: Baseline and Week 12

  18. Change From Baseline to Week 12 in the 'Instrumental Role' QLS Domain Score

    The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Instrumental Role domain score was calculated as the sum of 4 items (numbers 9 to 12) giving a range of 0 to 24, where the higher score indicated less unimpaired functioning.

    Time frame: Baseline and Week 12

  19. Change From Baseline to Week 12 in the TooL Total Score

    Tolerability and Quality of Life (TooL) is a patient-rated scale developed to measure the impact of side-effects on the quality of life in patients treated with antipsychotic medication. The TooL consists of 8 domains: mood (worry-upset), function capabilities, fatigue-weakness, weight gain, stiffness-tremor, physical restlessness, sexual dysfunction, and dizziness-nausea. Each domain was rated on a four-point scale from 1 (no impact) to 4 (maximum impact). Total scores ranged from 8 (no impact) to 32 (maximum impact).

    Time frame: Baseline and Week 12

  20. Change From Baseline to Week 12 in the WoRQ Total Score

    The Readiness for Work Questionnaire (WoRQ) is a clinician-rated scale designed to measure a schizophrenic patient's ability to work. The WoRQ consists of 8 items: the clinician had to rate 7 statements and answer 1 question. The statements were rated on a four-point scale, from 'strongly agree', 'agree', 'disagree' or 'strongly disagree' based on all material available (for example, personal notes, medical records, input from other health professionals, family members or caregivers); and in the final item, the clinician had to indicate if the patient was ready for work or not (by indicating either 'yes' or 'no'). Possible total scores range from 4 to 28. Lower WoRQ total scores indicate better functioning.

    Time frame: Baseline and Week 12

  21. Change From Baseline to Week 12 in ASEX Total Score

    The Arizona Sexual Experience Scale (ASEX) is a five-item, patient-rated scale that evaluates a patient's recent sexual experiences. The ASEX is used to identify individuals with sexual dysfunction. Patients were asked to assess their own experiences over the last week (for example, "How strong is your sex drive?", "Are your orgasms satisfying?") and respond on a six-point scale for each item. Possible total scores range from 5 to 30. Higher ASEX total scores indicate more sexual dysfunction (hypofunction).

    Time frame: Baseline and Week 12

  22. Patients Categorised As Sexually Dysfunctional Measured at Week 12 on the ASEX Scale

    The Arizona Sexual Experience Scale (ASEX) is a five-item, patient-rated scale that evaluates a patient's recent sexual experiences. The ASEX is used to identify individuals with sexual dysfunction. Patients were asked to assess their own experiences over the last week (for example, "How strong is your sex drive?", "Are your orgasms satisfying?") and respond on a six-point scale for each item. Possible total scores range from 5 to 30. Higher ASEX total scores indicate more sexual dysfunction (hypofunction). The presence of sexual dysfunction based on the ASEX scale was defined as an ASEX total score of ≥19, or a score of ≥5 on any item, or a score of ≥4 on any 3 items.

    Time frame: Week 12

07

Results

Posted May 16, 2016

Participant flow

Participant flow — Overall Study
MilestoneAripiprazole Once-monthly
Started88
Completed77
Not completed11
Withdrew: Adverse event5
Withdrew: Withdrawal by subject4
Withdrew: Lost to follow-up1
Withdrew: Other (no primary reason given)1

Outcome measures

PrimarySafety and Tolerability

Number of treatment emergent adverse events (TEAEs).

Time frame:
Up to 24 weeks and 4-week safety follow up
Reported as:
Number · number of events
Safety and Tolerability
number of eventsAripiprazole Once-monthly
Safety and Tolerability65
SecondaryChange From Baseline to Week 24 in SWN-S Total Score

The Subjective Well-Being under Neuroleptic Treatment - Short Version (SWN-S) is a patient-rated scale designed to measure subjective effects of neuroleptic drugs to psychopathology, quality of life, and compliance over the past 7 days. The 20 items (10 positive and 10 negative statements) are grouped in 5 subscales (mental functioning, self-control, physical functioning, emotional regulation and social integration). Each subscale contains 4 items. Each item was rated on a six-point Likert scale, from not at all to very much. A score was calculated for each subscale, and the total score ranged from 20 to 120, where the higher score indicated better well-being.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 24 in SWN-S Total Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 24 in SWN-S Total Score0.19 (-2.08 to 2.45)
SecondaryChange From Baseline to Week 24 in CGI-S Score

Clinical Global Impression - Severity of Illness (CGI-S) score provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 24 in CGI-S Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 24 in CGI-S Score-0.10 (-0.26 to 0.06)
SecondaryChange From Baseline to Week 24 in QLS Total Score

The Quality of Life Scale (QLS) is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). Definitions were provided for 4 anchor points of the 7 points. Each item had a brief description of the judgement to be made and a set of suggested probes for the clinician. The total score was calculated as the sum of all 21 items giving a range of 0 to 126, where the higher score indicated normal or unimpaired functioning.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 24 in QLS Total Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 24 in QLS Total Score2.32 (-1.21 to 5.85)
SecondaryChange From Baseline to Week 24 in the 'Common Objects and Activities' QLS Domain Score

The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Common Objects and Activities domain score was calculated as the sum of 2 items (numbers 18 and 19) giving a range of 0 to 12, where the higher score indicated less unimpaired functioning

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Change From Baseline to Week 24 in the 'Common Objects and Activities' QLS Domain Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 24 in the 'Common Objects and Activities' QLS Domain Score0.21 ± 1.29
SecondaryChange From Baseline to Week 24 in the 'Intrapsychic Foundations' QLS Domain Score

The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Intrapsychic Foundations domain score was calculated as the sum of 7 items (numbers 13 to 17 and 20 and 21) giving a range of 0 to 42, where the higher score indicated less unimpaired functioning

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Change From Baseline to Week 24 in the 'Intrapsychic Foundations' QLS Domain Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 24 in the 'Intrapsychic Foundations' QLS Domain Score0.72 ± 5.03
SecondaryChange From Baseline to Week 24 in the 'Interpersonal Relations' QLS Domain Score

The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Interpersonal Relations domain score was calculated as the sum of 8 items (numbers 1 to 8) giving a range of 0 to 48, where the higher score indicated less unimpaired functioning.

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Change From Baseline to Week 24 in the 'Interpersonal Relations' QLS Domain Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 24 in the 'Interpersonal Relations' QLS Domain Score0.58 ± 6.54
SecondaryChange From Baseline to Week 24 in the 'Instrumental Role' QLS Domain Score

The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Instrumental Role domain score was calculated as the sum of 4 items (numbers 9 to 12) giving a range of 0 to 24, where the higher score indicated less unimpaired functioning.

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Change From Baseline to Week 24 in the 'Instrumental Role' QLS Domain Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 24 in the 'Instrumental Role' QLS Domain Score0.42 ± 4.54
SecondaryChange From Baseline to Week 24 in the TooL Total Score

Tolerability and Quality of Life (TooL) is a patient-rated scale developed to measure the impact of side-effects on the quality of life in patients treated with antipsychotic medication. The TooL consists of 8 domains: mood (worry-upset), function capabilities, fatigue-weakness, weight gain, stiffness-tremor, physical restlessness, sexual dysfunction, and dizziness-nausea. Each domain was rated on a four-point scale from 1 (no impact) to 4 (maximum impact). Total scores ranged from 8 (no impact) to 32 (maximum impact).

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 24 in the TooL Total Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 24 in the TooL Total Score-0.47 (-1.16 to 0.22)
SecondaryChange From Baseline to Week 24 in the WoRQ Total Score

The Readiness for Work Questionnaire (WoRQ) is a clinician-rated scale designed to measure a schizophrenic patient's ability to work. The WoRQ consists of 8 items: the clinician had to rate 7 statements and answer 1 question. The statements were rated on a four-point scale, from 'strongly agree', 'agree', 'disagree' or 'strongly disagree' based on all material available (for example, personal notes, medical records, input from other health professionals, family members or caregivers); and in the final item, the clinician had to indicate if the patient was ready for work or not (by indicating either 'yes' or 'no'). Possible total scores range from 4 to 28. Lower WoRQ total scores indicate better functioning.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 24 in the WoRQ Total Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 24 in the WoRQ Total Score-0.53 (-1.21 to 0.15)
SecondaryChange From Baseline to Week 24 in ASEX Total Score

The Arizona Sexual Experience Scale (ASEX) is a five-item, patient-rated scale that evaluates a patient's recent sexual experiences. The ASEX is used to identify individuals with sexual dysfunction. Patients were asked to assess their own experiences over the last week (for example, "How strong is your sex drive?", "Are your orgasms satisfying?") and respond on a six-point scale for each item. Possible total scores range from 5 to 30. Higher ASEX total scores indicate more sexual dysfunction (hypofunction).

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 24 in ASEX Total Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 24 in ASEX Total Score-0.42 (-1.74 to 0.91)
SecondaryPatients Categorised As Sexually Dysfunctional Measured at Week 24 on the ASEX Scale

The Arizona Sexual Experience Scale (ASEX) is a five-item, patient-rated scale that evaluates a patient's recent sexual experiences. The ASEX is used to identify individuals with sexual dysfunction. Patients were asked to assess their own experiences over the last week (for example, "How strong is your sex drive?", "Are your orgasms satisfying?") and respond on a six-point scale for each item. Possible total scores range from 5 to 30. Higher ASEX total scores indicate more sexual dysfunction (hypofunction). The presence of sexual dysfunction based on the ASEX scale was defined as an ASEX total score of ≥19, or a score of ≥5 on any item, or a score of ≥4 on any 3 items.

Time frame:
Week 24
Reported as:
Number · participants
Patients Categorised As Sexually Dysfunctional Measured at Week 24 on the ASEX Scale
participantsAripiprazole Once-monthly
Patients Categorised As Sexually Dysfunctional Measured at Week 24 on the ASEX Scale31
SecondaryChange From Baseline to Week 12 in SWN-S Total Score

The Subjective Well-Being under Neuroleptic Treatment - Short Version (SWN-S) is a patient-rated scale designed to measure subjective effects of neuroleptic drugs to psychopathology, quality of life, and compliance over the past 7 days. The 20 items (10 positive and 10 negative statements) are grouped in 5 subscales (mental functioning, self-control, physical functioning, emotional regulation and social integration). Each subscale contains 4 items. Each item was rated on a six-point Likert scale, from not at all to very much. A score was calculated for each subscale, and the total score ranged from 20 to 120, where the higher score indicated better well-being.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in SWN-S Total Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 12 in SWN-S Total Score-1.57 (-4.19 to 1.05)
SecondaryChange From Baseline to Week 12 in CGI-S Score

Clinical Global Impression - Severity of Illness (CGI-S) score provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in CGI-S Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 12 in CGI-S Score0.00 (-0.14 to 0.14)
SecondaryChange From Baseline to Week 12 in QLS Total Score

The Quality of Life Scale (QLS) is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). Definitions were provided for 4 anchor points of the 7 points. Each item had a brief description of the judgement to be made and a set of suggested probes for the clinician. The total score was calculated as the sum of all 21 items giving a range of 0 to 126, where the higher score indicated normal or unimpaired functioning.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in QLS Total Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 12 in QLS Total Score2.08 (-0.80 to 4.97)
SecondaryChange From Baseline to Week 12 in the 'Common Objects and Activities' QLS Domain Score

The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Common Objects and Activities domain score was calculated as the sum of 2 items (numbers 18 and 19) giving a range of 0 to 12, where the higher score indicated less unimpaired functioning

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline to Week 12 in the 'Common Objects and Activities' QLS Domain Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 12 in the 'Common Objects and Activities' QLS Domain Score0.10 ± 1.16
SecondaryChange From Baseline to Week 12 in the 'Intrapsychic Foundations' QLS Domain Score

The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Intrapsychic Foundations domain score was calculated as the sum of 7 items (numbers 13 to 17 and 20 and 21) giving a range of 0 to 42, where the higher score indicated less unimpaired functioning

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline to Week 12 in the 'Intrapsychic Foundations' QLS Domain Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 12 in the 'Intrapsychic Foundations' QLS Domain Score0.73 ± 4.31
SecondaryChange From Baseline to Week 12 in the 'Interpersonal Relations' QLS Domain Score

The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Interpersonal Relations domain score was calculated as the sum of 8 items (numbers 1 to 8) giving a range of 0 to 48, where the higher score indicated less unimpaired functioning

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline to Week 12 in the 'Interpersonal Relations' QLS Domain Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 12 in the 'Interpersonal Relations' QLS Domain Score0.67 ± 4.83
SecondaryChange From Baseline to Week 12 in the 'Instrumental Role' QLS Domain Score

The QLS is a clinician-rated scale designed to assess deficit symptoms of schizophrenia and functioning during the preceding 4 weeks. The QLS consists of 21 items in 4 domains: Interpersonal Relations (eight items), Instrumental Role (four items), Intrapsychic Foundations (seven items), and Common Objects and Activities (two items). Each item was rated on a 7-point scale, from 0 (severe impairment) to 6 (normal or unimpaired functioning). The Instrumental Role domain score was calculated as the sum of 4 items (numbers 9 to 12) giving a range of 0 to 24, where the higher score indicated less unimpaired functioning.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline to Week 12 in the 'Instrumental Role' QLS Domain Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 12 in the 'Instrumental Role' QLS Domain Score0.02 ± 2.53
SecondaryChange From Baseline to Week 12 in the TooL Total Score

Tolerability and Quality of Life (TooL) is a patient-rated scale developed to measure the impact of side-effects on the quality of life in patients treated with antipsychotic medication. The TooL consists of 8 domains: mood (worry-upset), function capabilities, fatigue-weakness, weight gain, stiffness-tremor, physical restlessness, sexual dysfunction, and dizziness-nausea. Each domain was rated on a four-point scale from 1 (no impact) to 4 (maximum impact). Total scores ranged from 8 (no impact) to 32 (maximum impact).

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in the TooL Total Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 12 in the TooL Total Score-0.16 (-0.85 to 0.53)
SecondaryChange From Baseline to Week 12 in the WoRQ Total Score

The Readiness for Work Questionnaire (WoRQ) is a clinician-rated scale designed to measure a schizophrenic patient's ability to work. The WoRQ consists of 8 items: the clinician had to rate 7 statements and answer 1 question. The statements were rated on a four-point scale, from 'strongly agree', 'agree', 'disagree' or 'strongly disagree' based on all material available (for example, personal notes, medical records, input from other health professionals, family members or caregivers); and in the final item, the clinician had to indicate if the patient was ready for work or not (by indicating either 'yes' or 'no'). Possible total scores range from 4 to 28. Lower WoRQ total scores indicate better functioning.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in the WoRQ Total Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 12 in the WoRQ Total Score-0.55 (-1.20 to 0.11)
SecondaryChange From Baseline to Week 12 in ASEX Total Score

The Arizona Sexual Experience Scale (ASEX) is a five-item, patient-rated scale that evaluates a patient's recent sexual experiences. The ASEX is used to identify individuals with sexual dysfunction. Patients were asked to assess their own experiences over the last week (for example, "How strong is your sex drive?", "Are your orgasms satisfying?") and respond on a six-point scale for each item. Possible total scores range from 5 to 30. Higher ASEX total scores indicate more sexual dysfunction (hypofunction).

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in ASEX Total Score
units on a scaleAripiprazole Once-monthly
Change From Baseline to Week 12 in ASEX Total Score-0.74 (-2.03 to 0.56)
SecondaryPatients Categorised As Sexually Dysfunctional Measured at Week 12 on the ASEX Scale

The Arizona Sexual Experience Scale (ASEX) is a five-item, patient-rated scale that evaluates a patient's recent sexual experiences. The ASEX is used to identify individuals with sexual dysfunction. Patients were asked to assess their own experiences over the last week (for example, "How strong is your sex drive?", "Are your orgasms satisfying?") and respond on a six-point scale for each item. Possible total scores range from 5 to 30. Higher ASEX total scores indicate more sexual dysfunction (hypofunction). The presence of sexual dysfunction based on the ASEX scale was defined as an ASEX total score of ≥19, or a score of ≥5 on any item, or a score of ≥4 on any 3 items.

Time frame:
Week 12
Reported as:
Number · participants
Patients Categorised As Sexually Dysfunctional Measured at Week 12 on the ASEX Scale
participantsAripiprazole Once-monthly
Patients Categorised As Sexually Dysfunctional Measured at Week 12 on the ASEX Scale32

Adverse events

Collected over Treatment to end of study (up to 28 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole Once-monthly—3/88 (3.4%)6/88 (6.8%)
Most frequent serious events
Most frequent serious events
EventAripiprazole Once-monthly
Gastrooesophageal reflux diseaseGastrointestinal disorders1/88
AlcoholismPsychiatric disorders1/88
DysphoriaPsychiatric disorders1/88
Most frequent other events
Most frequent other events
EventAripiprazole Once-monthly
Weight increasedInvestigations6/88

Baseline characteristics

Demographic data is based on all patients who received at least one dose of IMP in Study 14724B.

Age, Continuous
Age, Continuous(years)Aripiprazole Once-monthly
Mean43.4 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole Once-monthly
Female36
Male52
08

Study locations

1 site
  • US006
    San Diego, California 92102, United States
09

References and documents

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01959035
Lead sponsor
H. Lundbeck A/S
Collaborators
Otsuka Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Oct 9, 2013
Start date
Oct 2013
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
May 16, 2016
Last update
Mar 17, 2017

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion